Abstract:The COVID pandemic fueled by emerging SARS-CoV-2 new variants of concern remains a major global health concern, and the constantly emerging mutations present challenges to current therapeutics. The spike glycoprotein is not only essential for the initial viral entry, but is also responsible for the transmission of SARS-CoV-2 components via syncytia formation. Spike-mediated cell-cell transmission is strongly resistant to extracellular therapeutic and convalescent antibodies via an unknown mechanism. Here, we describe the antibody-mediated spike activation and syncytia formation on cells displaying the viral spike. We found that soluble antibodies against receptor binding motif (RBM) are capable of inducing the proteolytic processing of spike at both the S1/S2 and S2' cleavage sites, hence triggering ACE2-independent cell-cell fusion. Mechanistically, antibody-induced cell-cell fusion requires the shedding of S1 and exposure of the fusion peptide at the cell surface. By inhibiting S1/S2 proteolysis, we demonstrated that cell-cell fusion mediated by spike can be re-sensitized towards antibody neutralization in vitro . Lastly, we showed that cytopathic effect mediated by authentic SARS-CoV-2 infection remain unaffected by the addition of extracellular neutralization antibodies. Hence, these results unveil a novel mode of antibody evasion and provide insights for antibody selection and drug design strategies targeting the SARS-CoV-2 infected cells. SARS-CoV-2 has been found to mediate breakthrough infections in vaccinated individuals and re-infections of convalescent patients, but the molecular mechanism of its immune escaping strategies remains elusive. Unlike virus-to-cell transmission, spike promotes SARS-CoV-2 cell-to-cell transmission, which is strongly resistant to extracellular antibodies and patient plasma. Here we show that receptor binding-motif antibodies mediate the ACE2-independent activation of spike at the cell plasma membrane. This mode of spike activation is enabled by the protease-mediated S1/S2 cleavage event and can be genetically and pharmacologically prevented. Through targeting the S1/S2 site, antibody neutralization against spike-mediated cell-cell fusion can be restored in various SARS-CoV-2 variants. Hence, these data highlight a role for S1/S2-cleaved spike and inform therapeutic strategies to restore antibody neutralization against cell-cell transmission of SARS-CoV-2.

Harnessing coronavirus spike proteins' binding affinity to ACE2 receptor through a novel baculovirus surface display system

Baculovirus Surface Display Of Sars Coronavirus (Sars-Cov) Spike Protein And Immunogenicity Of The Displayed Protein In Mice Models

Utilization of Recombinant Baculovirus Expression System to Produce the RBD Domain of SARS-CoV-2 Spike Protein

Display of receptor-binding domain of SARS-CoV-2 Spike protein variants on the <i>Saccharomyces cerevisiae</i> cell surface

High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2

Display of receptor-binding domain of SARS-CoV-2 Spike protein variants on the Saccharomyces cerevisiae cell surface

Engineered Trimeric ACE2 Binds Viral Spike Protein and Locks It in “Three-Up” Conformation to Potently Inhibit SARS-CoV-2 Infection

CD81 fusion alters SARS-CoV-2 Spike trafficking

Phage Display-Derived Compounds Displace hACE2 from Its Complex with SARS-CoV-2 Spike Protein

Potential use of the S-protein–Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019

The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Immunization with the Receptor-Binding Domain of SARS-CoV-2 Elicits Antibodies Cross-Neutralizing SARS-CoV-2 and SARS-CoV Without Antibody-Dependent Enhancement

A hydrophobic-interaction-based mechanism trigger docking between the SARS CoV 2 spike and angiotensin-converting enzyme 2

An Integrated Platform for Serological Detection and Vaccination of COVID-19

Antibody-mediated spike activation promotes cell-cell transmission of SARS-CoV-2

A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity

Binding affinity between coronavirus spike protein and human ACE2 receptor

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein